HOME > BUSINESS
BUSINESS
- Velcade Approved in US for Treatment-Naïve Mantle Cell Lymphoma: Takeda
October 14, 2014
- GSK to Market Authorized Generics through Aspen Japan Unit
October 10, 2014
- Kowa Loses Trademark Suit against Meiji Seika Pharma
October 10, 2014
- Ethical Drug Sales Down 7.2% in August, Switch to Generics Accelerated: Crecon Report
October 10, 2014
- AZ’s US Subsidiary Obtains Exclusive Rights to Shionogi’s Biologic Research Program
October 9, 2014
- Ono Revises Semiannual Forecasts Downward
October 9, 2014
- Shire Japan Takes Aim at $500 Million Sales in 10 Years
October 8, 2014
- Tsumura to Increase Sales of 4 Products in Field of Dermatology by 20% in FY2015
October 8, 2014
- Nipro Pharma Ties Up with Unilab of Philippines as Part of Efforts to Develop Asian Market
October 8, 2014
- Cost-Effective Assessment Could Hamper Patient Access to New Drugs: Chugai CEO
October 7, 2014
- Chugai, Roche Chiefs Were in Talks on Recent Deal Change from 2 Years Ago
October 7, 2014
- Takeda Ordered to Pay Over US$2 Million in Philadelphia Actos Suit
October 7, 2014
- Avigan-Administered French Ebola Patient Recovers
October 7, 2014
- AnGes MG Commences Patient Registration in US for Collategene PIII Study
October 7, 2014
- Januvia Remains No. 1, Trazenta Climbs to No. 2 in GP Market in Anterio’s “Mind Share” Ranking for August
October 6, 2014
- JCR Pharmaceuticals Hopes to Make Japan’s First Cell Product into New Profit Pillar
October 6, 2014
- Takeda Directors Face 3-Month Pay Cut over CASE-J Issue
October 6, 2014
- Daiichi Sankyo Opens Representative Office in Vietnam
October 6, 2014
- Takeda to Invest in Alfresa Corporation’s Vaccine-Related Subsidiary
October 6, 2014
- Eisai Launches Halaven in Australia
October 3, 2014
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…